The alternative complement pathway is one of the three major activation pathways of the complement system, a network of circulating and cell-associated proteins involved in immune defense. It forms part of innate immunity and can operate without antibodies. Its defining feature is a self-amplifying reaction in which complement component C3 is cleaved and its fragment C3b supports further C3 cleavage. When this reaction proceeds on a susceptible surface, it promotes microbial recognition, inflammation, and, through the terminal complement pathway, membrane damage. Regulatory proteins normally restrict amplification on host tissues.
Relationship to other complement pathways
The complement system has three conventionally recognized activation routes: the alternative pathway, the classical pathway, and the lectin pathway. They differ in their initiating mechanisms and early components but converge on C3 cleavage.
The classical pathway commonly begins with recognition of antibody-containing complexes, although it can also be activated independently of antibodies. The lectin pathway begins with recognition of particular carbohydrate or acetylated molecular patterns. The alternative pathway can begin through low-level spontaneous changes in C3 and becomes strongly amplified where deposited C3b escapes rapid inactivation.
The alternative pathway is therefore both an activation route and an amplification loop. C3b generated by the classical or lectin pathway can enter the same amplification machinery. Consequently, alternative-pathway activity during an immune response does not necessarily mean that the response began through this pathway.
Components and activation mechanism
The core components are C3, factor B, and factor D. Properdin stabilizes the active surface-bound enzyme complex. Magnesium ions are required for efficient assembly of the C3b–factor B complex.
Basal C3 activation: tickover
Native C3 contains an internal thioester bond. A small proportion of circulating C3 undergoes spontaneous hydrolysis of this bond, generating a conformationally altered molecule conventionally written as . This process is called tickover.
can bind factor B. Factor D then cleaves the bound factor B into Ba and Bb, leaving Bb associated with the complex:
The resulting fluid-phase complex can cleave C3 into C3a and C3b. Tickover provides a conventional explanation for basal alternative-pathway initiation, but it is not the only source of C3b available to the pathway.
Surface attachment and C3 convertase formation
Cleavage of C3 exposes a short-lived reactive thioester in newly generated C3b. Some C3b attaches covalently to nearby molecules on a microbial or other surface; much of the remainder reacts with water and loses this attachment capacity.
Surface-bound C3b binds factor B, which is cleaved by factor D:
The product, C3bBb, is the alternative-pathway C3 convertase. A convertase is an enzyme complex that cleaves another complement component. In this complex, Bb supplies the proteolytic activity, while C3b supports assembly and substrate interaction.
Factor D acts preferentially on factor B after factor B has bound C3b or , helping to confine its activity to assembled precursor complexes.
Amplification and properdin
C3bBb cleaves additional C3, producing more C3b that can attach nearby and assemble further convertases. This creates a positive feedback loop.
C3bBb is intrinsically unstable. Properdin, a positive regulator of complement, binds and stabilizes the convertase, extending its functional lifetime. Properdin can also associate with certain surfaces and facilitate local complement activation in particular experimental and biological settings. Its broadly established role, however, is stabilization and enhancement of alternative-pathway convertases; it should not be treated as a universal initiating receptor.
C5 convertase and terminal activation
Association of additional C3b with the convertase produces a complex with C5-cleaving activity, conventionally written as . C5 cleavage releases C5a and C5b.
C5b initiates assembly of the membrane attack complex, composed of C5b, C6, C7, C8, and multiple C9 molecules. This terminal complex inserts into susceptible membranes and can disrupt their integrity. The terminal pathway is shared by all three complement activation routes.
Biological functions
Alternative-pathway amplification supports several distinct functions:
- Opsonization: C3b and its breakdown product iC3b coat target surfaces. Complement receptors on neutrophils, macrophages, and other cells recognize these fragments, promoting phagocytosis.
- Inflammatory signaling: C3a and especially C5a act through specific receptors to influence leukocyte recruitment, activation, and other inflammatory responses.
- Direct membrane injury: Terminal complement complexes can kill susceptible targets, particularly certain Gram-negative bacteria. Not all microorganisms are susceptible to complement-mediated lysis.
- Support of broader immune responses: Complement-tagged material can interact with immune-cell receptors and contribute to the connections between innate and adaptive immunity.
The pathway does not identify pathogens solely through a single pathogen-specific receptor. Its selectivity depends substantially on whether a surface permits amplification or instead recruits and supports complement regulators.
Regulation and host protection
Because C3b can attach near its site of generation, complement activation poses a risk to host cells as well as microbes. Regulation acts at several stages: convertase assembly, convertase decay, C3b inactivation, and terminal-complex formation.
Factor H and factor I
Factor H is a major soluble inhibitor of the alternative pathway. It competes with factor B for C3b binding, accelerates dissociation of Bb from C3bBb, and serves as a cofactor for factor I.
Factor H recognizes combinations of deposited C3b and host-associated surface features, including sialic acids and particular glycosaminoglycans. This helps concentrate protection on many host surfaces.
Factor I is a protease that cleaves C3b in the presence of appropriate cofactors. Its cleavage products, including iC3b, cannot assemble the alternative-pathway C3 convertase. Nevertheless, iC3b retains important recognition functions, especially in phagocytosis. C3b inactivation therefore stops amplification without immediately eliminating every immune function of the deposited fragment.
Membrane-associated regulators
Host cell membranes carry additional regulators:
- CD55, or decay-accelerating factor, promotes convertase dissociation.
- CD46, or membrane cofactor protein, supports factor I-mediated cleavage of C3b.
- Complement receptor 1, or CD35, has both decay-accelerating and cofactor activities.
- CD59 inhibits terminal membrane attack complex assembly rather than the alternative C3 convertase itself.
Regulator expression differs among cell types. Protection is therefore distributed across overlapping soluble and membrane-bound mechanisms.
Some microorganisms evade complement by recruiting host factor H or producing proteins that interfere with complement activation. Thus, the presence of a microbial surface does not guarantee effective alternative-pathway attack.
Clinical significance
Defective alternative-pathway activity and excessive activation have different consequences.
Inherited deficiencies of factor B, factor D, or properdin can impair host defense. Properdin deficiency is particularly associated with susceptibility to invasive meningococcal disease. Clinical effects depend on the affected component and on the remaining complement functions.
Conversely, inadequate regulation can cause complement-mediated tissue injury. Established disease associations include:
- Complement-mediated atypical hemolytic uremic syndrome: a form of thrombotic microangiopathy associated in some patients with variants affecting complement regulation or with antibodies against factor H.
- C3 glomerulopathy: a group of kidney diseases characterized by dominant glomerular C3 deposition, frequently associated with alternative-pathway dysregulation. Acquired factors can include C3 nephritic factors, antibodies that stabilize alternative-pathway convertases.
- Paroxysmal nocturnal hemoglobinuria: an acquired blood-cell disorder involving loss of glycosylphosphatidylinositol-anchored proteins, including CD55 and CD59, from affected cells. Reduced complement protection allows complement-mediated injury, with alternative-pathway amplification contributing to disease mechanisms.
These disorders are not interchangeable, and an association with complement does not imply that every affected person has an identifiable inherited complement defect. Therapeutic complement inhibition can target the alternative pathway or shared downstream components; the biological effects depend on the point of inhibition.
Laboratory assessment
Alternative-pathway function can be assessed with functional assays, commonly termed AH50 or AP50 assays. Traditional hemolytic methods measure lysis of susceptible erythrocytes under conditions that favor alternative-pathway activity. Magnesium–EGTA buffers are commonly used: EGTA limits calcium-dependent classical and lectin pathway activation while sufficient magnesium remains available for the alternative pathway.
Functional results reflect the integrity of the pathway as a whole, including shared terminal components. Reduced activity can result from component deficiency, complement consumption, inhibition, or sample deterioration; it does not by itself identify the affected protein.
Measurements of individual components, activation fragments, regulatory proteins, autoantibodies, and relevant genetic variants provide different kinds of information. Circulating C3 concentration alone is not a direct measure of alternative-pathway activity. Complement can also activate after blood collection, making specimen handling important for interpreting activation-product measurements.
Historical development
In 1954, Louis Pillemer and colleagues described the properdin system, helping establish that complement-mediated defense could occur independently of the then-dominant antibody-dependent model. Early interpretations assigned properdin a central initiating role.
Subsequent biochemical work established the roles of C3, factors B and D, convertase formation, and spontaneous C3 hydrolysis. The term alternative pathway came to describe this antibody-independent machinery. Modern accounts emphasize both its capacity for activation and its broader role in amplifying C3b deposition initiated through any complement pathway.